BioSpace News Archive

Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.

GRIP Molecular is pleased to announce the formation of a Board of Directors with Edward Ludwig accepting the role of Chairman of the Board

NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement).

Ohio-based company continues to help international communities plan COVID-19 Vaccine distribution plans by sharing learned experiences with the likes of Walgreens, Puerto Rico National Guard, University of North Carolina and others, providing flexibility as vaccine requirements adjust.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced a positive opinion has been adopted from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA

Ermium Therapeutics SAS, a research-stage biotechnology company developing innovative therapies for auto-immune diseases is announcing today the expansion of the Company executive management team with the appointment of Dr Annegret Van der Aa as Chief Scientific Officer (CSO) and Chief Development Officer (CDO).

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that The Centers for Medicare and Medicaid Services (CMS) has included Ambulatory Surgical Centers (ASC) as an approved site of service for Transcervical Uterine Fibroid Ablation (TFA),

Abaco Systems, Inc. announces a design win award of $3 million, with a long-term value of $30 million, supporting a medical device that uses low-coherence light to capture micrometer-resolution in two and three dimensional images.

CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of CITrials, a southern California-based clinical research firm with three sites serving Los Angeles, Orange, and Riverside/San Bernardino counties

ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated and stabilized with oral medications or other, shorter-interval Buprenorphine LAIs.